Jeannine Roth

Mar 8, 2024 | onlinelibrary.wiley.com | J. Helen Cross |Arturo Benítez |Jeannine Roth |J. Scott Andrews

Reducing the high clinical symptom burden of LGS could increase quality of life of patients and caregivers LGS is associated with high direct costs due to health care resource use and medications; data on indirect costs are lacking Pharmacoresistance is common, and most individuals with LGS require polytherapy and changes to treatment over time There is an unmet need for treatments that address the nonseizure symptoms of LGS There is a need for a greater understanding of and better...